We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Mesalamine for Uncomplicated Diverticular Disease: a Randomized, Double-blind, Placebo-controlled Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01627262
Recruitment Status : Completed
First Posted : June 25, 2012
Last Update Posted : January 21, 2016
Information provided by (Responsible Party):
Dr. Falk Pharma GmbH

Brief Summary:
The purpose of this study is to determine whether mesalamine is effective in the treatment of uncomplicated diverticular disease by reducing the pain.

Condition or disease Intervention/treatment Phase
Colonic Diverticulosis Drug: Mesalamine Drug: Placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 123 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Double-blind, Randomised, Placebo-controlled, Parallel-group, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Mesalazine Pellets vs. Placebo in Diverticular Disease
Study Start Date : May 2002
Primary Completion Date : August 2004
Study Completion Date : April 2006

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Placebo Comparator: Placebo Drug: Placebo
3x1000mg placebo granules per day
Other Name: Placebo granules
Experimental: Mesalamine Drug: Mesalamine
3x1000mg mesalamine granules per day
Other Name: Salofalk granules

Primary Outcome Measures :
  1. The change in intensity of lower abdominal pain during the first four weeks of treatment (SPID 0-28) [ Time Frame: 4 weeks ]
    The change in intensity of lower abdominal pain during the first four weeks of treatment, defined as the cumulative difference of the daily pain intensity score from the first day of study medication intake (day 1) to week 4

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   45 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of diverticular disease with acute pain without serious complications
  • Lower abdominal pain of moderate or severe intensity at least during the last 4 days before study inclusion

Exclusion Criteria:

  • Chronic inflammatory bowel disease
  • Fever or other signs of serious complications.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01627262

Ev. Krankenhaus Kalk, University of Cologne
Köln, Germany, 51103
Sponsors and Collaborators
Dr. Falk Pharma GmbH
Principal Investigator: Wolfgang Kruis, MD Ev. Krankenhaus Kalk, University of Cologne

Responsible Party: Dr. Falk Pharma GmbH
ClinicalTrials.gov Identifier: NCT01627262     History of Changes
Other Study ID Numbers: SAG-20/DIV
First Posted: June 25, 2012    Key Record Dates
Last Update Posted: January 21, 2016
Last Verified: January 2016

Keywords provided by Dr. Falk Pharma GmbH:
diverticular disease
colonic diverticulosis

Additional relevant MeSH terms:
Diverticulosis, Colonic
Pathological Conditions, Anatomical
Colonic Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents